Get the Stockscreener App
33.19
0.76%
0.25
Viking Therapeutics Inc stock is traded at $33.19, with a volume of 1.18M.
It is up +0.76% in the last 24 hours and down -12.59% over the past month.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
See More
Previous Close:
$32.94
Open:
$32.56
24h Volume:
1.18M
Relative Volume:
0.52
Market Cap:
$3.87B
Revenue:
-
Net Income/Loss:
$-472.34M
P/E Ratio:
-8.0055
EPS:
-4.1459
Net Cash Flow:
$-340.33M
1W Performance:
-3.12%
1M Performance:
-12.59%
6M Performance:
+14.45%
1Y Performance:
-17.52%
1-Day Range:
$32.33
$33.28
1-Week Range:
$32.33
$34.85
52-Week Range:
$22.96
$43.15
Viking Therapeutics Inc Stock (VKTX) Company Profile
Name
Viking Therapeutics Inc
Sector
Industry
Phone
858-704-4660
Address
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
33.19 | 3.97B | 0 | -472.34M | -340.33M | -4.1459 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-26-26 | Initiated | Wolfe Research | Peer Perform |
| Oct-29-25 | Initiated | Canaccord Genuity | Buy |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-25 | Initiated | Goldman | Neutral |
| Feb-13-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-07-25 | Initiated | Citigroup | Neutral |
| Dec-02-24 | Initiated | Piper Sandler | Overweight |
| Nov-22-24 | Initiated | B. Riley Securities | Buy |
| Nov-04-24 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-24 | Initiated | JP Morgan | Overweight |
| Jun-27-24 | Initiated | Morgan Stanley | Overweight |
| May-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-26-24 | Reiterated | Oppenheimer | Outperform |
| Mar-07-24 | Initiated | Jefferies | Buy |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| May-31-23 | Resumed | ROTH MKM | Buy |
| Mar-28-23 | Reiterated | Maxim Group | Buy |
| Mar-17-23 | Initiated | Stifel | Buy |
| Jul-29-21 | Resumed | BTIG Research | Buy |
| May-25-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jun-05-20 | Initiated | BMO Capital Markets | Outperform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| May-01-20 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-25-19 | Initiated | Stifel | Buy |
| Mar-29-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-14-19 | Reiterated | Maxim Group | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Mkt Perform |
| Dec-12-18 | Initiated | B. Riley FBR | Buy |
| Nov-19-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-18-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-18-18 | Reiterated | Maxim Group | Buy |
| Sep-18-18 | Reiterated | Raymond James | Outperform |
| Jul-20-18 | Initiated | SunTrust | Buy |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-01-18 | Reiterated | Laidlaw | Buy |
| May-31-18 | Reiterated | Maxim Group | Buy |
| Mar-26-18 | Resumed | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | Maxim Group | Buy |
| Nov-21-17 | Initiated | ROTH Capital | Buy |
View All
Viking Therapeutics Inc Stock (VKTX) Latest News
VKTX Stock Clocks Best Day In Nearly 3 Months On Obesity Pipeline Optimism, Buyout Speculation - Stocktwits
(VKTX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
LLY, NVO Stocks Led May’s GLP-1 Rally — But This Smaller ‘Differentiated Player’ Got A Bold 160% Upside Call - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
Viking Therapeutics Inc (VKTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - tradingkey.com
Viking Therapeutics Moves Closer To Challenging Ozempic With Phase 3 Trial Progress - Stocktwits
Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished - AOL.com
VKTX Maintained by JP Morgan -- Price Target Lowered to $65 - GuruFocus
JPMorgan Chase & Co. Issues Pessimistic Forecast for Viking Therapeutics (NASDAQ:VKTX) Stock Price - MarketBeat
VKTX Stock Outpaces LLY, ALT Ahead Of Earnings – Retail Eyes Breakout Ahead - Stocktwits
A New GLP-1 Challenger? Early Data Shows Viking's New Obesity Drug Tops Novo Rival - Stocktwits
Viking Therapeutics Inc (VKTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics? - Yahoo Finance
VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? - Stocktwits
Royal Bank of Canada Decreases Stock Position in Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics, Inc. $VKTX Stake Raised by Dimensional Fund Advisors LP - MarketBeat
Viking Therapeutics Inc (VKTX) Stock News Today - TradingKey
Viking Therapeutics: Mysterious GLP-1 Player With A Key Catalyst Due Q3 (Q2 Earnings Overview) - Seeking Alpha
First Trust Advisors LP Acquires Shares of 105,570 Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Viking Therapeutics, Inc. (VKTX) - DirectorsTalk Interviews
Viking Therapeutics, Inc. (VKTX) options chain - Yahoo Finance Australia
Viking Therapeutics Stock Moves Lower: What's Going On? - TradingView
VKTX Stock Lags GLP-1 Peers In July — But Viking CEO Says Its Obesity Drug Could Offer What Rivals Can’t - Stocktwits
This Insider Has Just Sold Shares In Viking Therapeutics - simplywall.st
Viking Therapeutics reports Q2 loss, R&D spend drives net loss; cash $502M at June 30, 2026 - TradingView
ADAR1 Capital Management LLC Increases Position in Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics (VKTX) Q2 Earnings Preview: Market Pricing i - GuruFocus
Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates? - Yahoo Finance
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic? - Yahoo Finance
Viking Therapeutics, Inc. (VKTX) Stock Analysis: Exploring a 165% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Eversept Partners LP Takes Position in Viking Therapeutics, Inc. $VKTX - MarketBeat
VKTX|Viking Therapeutics Inc|Price:34.880|Chg%:+0.090 - TradingKey
Viking Therapeutics Inc expected to post a loss of $1.25 a shareEarnings Preview - TradingView
Insiders At Viking Therapeutics Sold US$15m In Stock, Alluding To Potential Weakness - Moomoo
Viking Therapeutics (NASDAQ:VKTX) Stock in Focus Ahead of Cash-Burn Scrutiny, Earnings Set for July 29 - TechStock²
VKTX Stock Rises After-Hours: CNBC Flags Viking As Likely Buyout Target This Year As Big Pharma Hunts Next GLP-1 Winner - Stocktwits
Viking Therapeutics, Inc. Revenue Breakdown – DUS:1VT - TradingView
Viking Therapeutics Inc (VKTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Viking Therapeutics Inc (VKTX) Cash Flow - TradingKey
TradingKey - TradingKey
Viking Therapeutics Inc (VKTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Viking Therapeutics Inc (VKTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
VKTX Stock Draws Fresh Attention Ahead Of Earnings: Wall Street Sees Over 170% Upside As GLP-1 Race Burns Hot - Stocktwits
Viking Therapeutics Inc (VKTX) Institutional Confidence - TradingKey
VKTX|Viking Therapeutics Inc|Price:34.770|Chg%:-0.620 - TradingKey
Viking Therapeutics Inc (VKTX) Fundamental & Financial Data - Stocktwits
VKTX: Viking Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Viking Therapeutics (VKTX.US) will release its earnings report after market close on July 29. - 富途牛牛
Viking Therapeutics Inc (VKTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Viking Therapeutics (VKTX) Stock Could Be Overvalued On Fresh Diabetes Therapy News - Yahoo Finance
Viking Therapeutics Inc Stock (VKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):